

# Anthony E Lang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11819126/publications.pdf>

Version: 2024-02-01

542  
papers

76,057  
citations

767

119  
h-index

642

256  
g-index

573  
all docs

573  
docs citations

573  
times ranked

42686  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	2.8	5
2	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 1: Genetic Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 297-310.	1.5	2
3	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 2: Acquired Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 311-325.	1.5	2
4	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. <i>Human Brain Mapping</i> , 2022, 43, 2089-2108.	3.6	17
5	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	2.6	3
6	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring". <i>Movement Disorders Clinical Practice</i> , 2022, 9, 501-507.	1.5	2
7	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	4.6	4
8	<scp>DYT</scp>4 (Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.	1.5	5
9	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	3.9	9
10	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	3.3	8
11	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	3.9	11
12	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force "An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	3.9	49
13	The microbiome-gut-brain axis in Parkinson disease "from basic research to the clinic. <i>Nature Reviews Neurology</i> , 2022, 18, 476-495.	10.1	94
14	Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 15-17.	2.2	1
15	Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.	1.1	100
16	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021, 268, 3135-3143.	3.6	46
17	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266.	3.9	0
18	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 171-177.	3.9	3

#	ARTICLE	IF	CITATIONS
19	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021, 36, 999-1005.	3.9	5
20	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.	5.3	99
21	DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.	1.1	9
22	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 103-108.	1.4	1
23	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.	0.5	1
24	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.	2.8	14
25	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021, 36, 277-277.	3.9	11
26	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	1.3	3
27	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.	7.6	2
28	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1125-1125.	3.9	1
29	Reply to: "The Logic and Pitfalls of Parkinson's as Brain-First Versus Body-First Subtypes". <i>Movement Disorders</i> , 2021, 36, 786-787.	3.9	2
30	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 594-599.	1.5	2
31	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	3.9	28
32	Teaching Video Neurolmage: "Weighing in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971.	1.1	1
33	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.	3.9	4
34	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021, 36, 1483-1484.	3.9	17
35	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	3.9	4
36	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	5.3	30
38	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343.	1.9	0
39	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 997-1011.	1.5	7
40	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	4.1	7
41	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.	2.5	2
42	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports</i> (discontinued), 2021, 9, e04712.	0.5	1
43	The Discovery of $\alpha$ -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1189-1193.	1.5	1
44	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.	30.7	63
45	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	3.8	14
46	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	3.1	8
47	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.	1.2	10
48	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	1.8	9
49	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.1	58
50	Validation of the Movement Disorder Society Criteria for the Diagnosis of $\alpha$ -Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
51	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 79-84.	1.8	44
52	The Interaction Between Neuroinflammation and $\beta$ -Amyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	4.0	23
53	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.	1.5	27
54	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 360-362.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.	2.6	18
56	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	2.2	8
57	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	2.2	11
58	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	2.8	4
59	Nonsteroidal <scp>Anti-inflammatory</scp> Use and <scp><i>LRRK2</i></scp> Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	3.9	57
60	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	10.2	2
61	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198.	2.2	8
62	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	2.2	10
63	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.	3.9	24
64	<scp><i>Helicobacter pylori</i></scp> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2250-2260.	3.9	45
65	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	2.4	65
66	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
67	<scp>Age-Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	3.9	4
68	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.	2.8	14
69	Parkinson's Disease, <scp><i>NOTCH3</i></scp> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	3.9	18
70	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1047-1055.	2.8	3
71	CDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	2.8	63
72	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , The, 2020, 19, 452-461.	10.2	104

#	ARTICLE	IF	CITATIONS
73	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	1.9	77
74	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	2.4	7
75	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.1	103
76	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.	2.2	6
77	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80.	2.2	2
78	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	2.2	15
79	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020, 143, e36-e36.	7.6	7
80	Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 55.	2.0	0
81	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.	4.1	26
82	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 782-784.	0.5	2
83	Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. <i>JAMA Neurology</i> , 2019, 76, 985.	9.0	0
84	ADCY5â€”Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	1.5	31
85	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	2.8	29
86	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.	1.1	73
87	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€• <i>Parkinsonism and Related Disorders</i> , 2019, 66, 245-246.	2.2	0
88	&lt;p&gt;Orthostatic hypotension and dementia incidence: links and implications&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	2.2	17
89	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinsonâ€™s disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	2.5	10
90	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	8.0	70

#	ARTICLE	IF	CITATIONS
91	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.1	89
92	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	27.0	225
93	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.	2.2	21
94	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
95	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.	2.2	7
96	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	1.8	13
97	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019, 132, 104462.	4.4	71
98	Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.	1.5	15
99	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.	1.5	4
100	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 349-351.	2.2	2
101	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
102	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
103	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.1	194
104	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	2.0	24
105	Dancing Dorsal Quadrilaterals. <i>JAMA Neurology</i> , 2019, 76, 351.	9.0	11
106	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 228-230.	2.2	6
107	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	1.9	24
108	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.	4.4	14

#	ARTICLE	IF	CITATIONS
109	Gut-brain axis and the spread of $\alpha$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	3.9	144
110	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	1.9	21
111	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	3.9	12
112	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	3.9	275
113	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.	5.3	51
114	Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.	1.1	3
115	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018, 190, E50-E52.	2.0	6
116	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	3.9	37
117	Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 66-74.	1.5	7
118	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.	2.2	8
119	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	1.9	76
120	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	2.7	67
121	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 174-176.	3.9	45
122	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	2.3	36
123	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.	2.1	33
124	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	2.8	48
125	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	2.4	19
126	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	2.8	18



#	ARTICLE	IF	CITATIONS
127	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	5.3	225
128	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.	3.9	25
129	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	1.2	25
130	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018, 31, 484-490.	3.6	69
131	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	2.2	53
132	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	2.2	63
133	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	3.4	64
134	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.	3.9	12
135	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.1	35
136	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.	1.5	4
137	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.	3.9	3
138	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114
139	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	3.9	171
140	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	9.0	455
141	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	2.8	10
142	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	2.8	25
143	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 58-64.	2.2	71
144	Action Myoclonus and Seizure in Kufor-Rakeb Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 195-199.	1.5	13

#	ARTICLE	IF	CITATIONS
145	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	10.1	141
146	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	3.9	18
147	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	3.9	74
148	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	4.3	48
149	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.	1.9	24
150	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.	3.9	31
151	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	3.9	145
152	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links <i>SCN1A</i> to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.	5.1	32
153	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
154	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	9.0	60
155	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
156	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	10.2	131
157	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 772-774.	1.5	5
158	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	10.2	303
159	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.	7.6	5
160	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	8.0	177
161	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.	3.9	29
162	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017, 140, 1371-1383.	7.6	41

#	ARTICLE	IF	CITATIONS
163	Parkinson disease. Nature Reviews Disease Primers, 2017, 3, 17013.	30.5	3,048
164	Placebos in clinical trials: unravelling a complex phenomenon. Lancet Neurology, The, 2017, 16, 28-29.	10.2	6
165	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. Journal of Pediatrics, 2017, 181, 306-308.e1.	1.8	24
166	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.5	72
167	Caffeine as symptomatic treatment for Parkinson disease (Caf©-PD). Neurology, 2017, 89, 1795-1803.	1.1	102
168	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. Annals of Neurology, 2017, 82, 503-513.	5.3	133
169	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. Movement Disorders, 2017, 32, 1465-1473.	3.9	19
170	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 2017, 44, 447-448.	0.5	3
171	Is there even such a thing as âœœidiopathic normal pressure hydrocephalusâ€?. Annals of Neurology, 2017, 82, 1032-1032.	5.3	2
172	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADYâ€PD III). Annals of Clinical and Translational Neurology, 2017, 4, 360-368.	3.7	59
173	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. Movement Disorders Clinical Practice, 2017, 4, 39-41.	1.5	3
174	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. Human Brain Mapping, 2017, 38, 283-292.	3.6	30
175	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). Journal of Alzheimer's Disease, 2017, 59, 707-721.	2.6	54
176	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0173944.	2.5	17
177	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
178	The long-term outcome of orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309942.	1.9	100
179	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2016, 8, 259.	3.4	53
180	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurology, The, 2016, 15, 954-966.	10.2	100

#	ARTICLE	IF	CITATIONS
181	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	3.9	464
182	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.	1.5	22
183	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.	1.5	8
184	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016, 37, 1375-1392.	3.6	36
185	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	3.9	68
186	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.	3.9	48
187	“Under pressure”: is there a link between orthostatic hypotension and cognitive impairment in $\pm$ -synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	1.9	75
188	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
189	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	82
190	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	2.2	33
191	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
192	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 53-58.	1.5	1
193	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	3.9	91
194	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	3.9	47
195	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1191-1203.	1.9	48
196	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	5.3	61
197	$\pm$ -Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	8.6	120
198	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.	1.5	10

#	ARTICLE	IF	CITATIONS
199	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	10.1	279
200	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404.	3.6	64
201	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.	3.1	16
202	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	2.2	35
203	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.	2.5	24
204	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	3.9	188
205	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
206	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 295-298.	1.5	6
207	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.	3.9	8
208	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.	1.2	49
209	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.	5.3	9
210	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	5.3	224
211	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [ <sup>11</sup> C]-(+)-PHNO and [ <sup>11</sup> C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015, 36, 2592-2601.	3.6	17
212	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	3.9	88
213	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	2.5	95
214	Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	9.0	272
215	<i>Helicobacter pylori</i> infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 221-225.	2.2	107
216	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.	10.2	25

#	ARTICLE	IF	CITATIONS
217	Colonic mucosal $\alpha$ -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.1	130
218	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
219	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.1	112
220	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.	10.2	2
221	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	3.9	92
222	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.	2.4	222
223	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015, 85, 425-432.	1.1	39
224	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa+carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.	2.2	23
225	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	4.2	108
226	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.	1.4	4
227	Parkinson's disease. <i>Lancet</i> , The, 2015, 386, 896-912.	13.7	4,079
228	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.	21.4	237
229	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.	2.8	61
230	Levodopa+carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	3.9	199
231	Mutation analysis of <i>CHCHD10</i> in different neurodegenerative diseases. <i>Brain</i> , 2015, 138, e380-e380.	7.6	86
232	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	3.9	63
233	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.	3.1	36
234	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 269-280.	5.3	93

#	ARTICLE	IF	CITATIONS
235	Imaging changes associated with cognitive abnormalities in Parkinson's disease. Brain Structure and Function, 2015, 220, 2249-2261.	2.3	41
236	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. Neurology, 2014, 82, 2250-2251.	1.1	56
237	Peroxisomal D-bifunctional protein deficiency. Neurology, 2014, 82, 963-968.	1.1	73
238	Another face of placebo: The lessebo effect in Parkinson disease. Neurology, 2014, 82, 1402-1409.	1.1	45
239	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology, 2014, 82, 1791-1797.	1.1	147
240	'Don't delay, start today': delaying levodopa does not delay motor complications. Brain, 2014, 137, 2628-2630.	7.6	26
241	Global investigation and meta-analysis of the <i>C9orf72</i> (G <sub>4</sub> C <sub>2</sub> ) repeat in Parkinson disease. Neurology, 2014, 83, 1906-1913.	1.1	56
242	Alimentary, my dear Watson? The challenges of enteric $\alpha$ -synuclein as a Parkinson's disease biomarker. Movement Disorders, 2014, 29, 444-450.	3.9	74
243	Tremor in Spinocerebellar Ataxia Type 12. Movement Disorders Clinical Practice, 2014, 1, 76-78.	1.5	6
244	Subthalamic nucleus deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better. Movement Disorders, 2014, 29, 1751-1756.	3.9	68
245	Functional/psychogenic movement disorders: Do we know what they are?. Movement Disorders, 2014, 29, 1696-1697.	3.9	13
246	Pharmacological Treatment of Parkinson Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1670.	7.4	1,097
247	Dopamine agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. Human Brain Mapping, 2014, 35, 2499-2506.	3.6	64
248	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. Journal of Neural Transmission, 2014, 121, 49-57.	2.8	19
249	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain, 2014, 137, 565-575.	7.6	116
250	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. Movement Disorders Clinical Practice, 2014, 1, 67-69.	1.5	14
251	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. Brain, 2014, 137, 2143-2154.	7.6	140
252	Designing Clinical Trials for Dystonia. Neurotherapeutics, 2014, 11, 117-127.	4.4	15



#	ARTICLE	IF	CITATIONS
253	The treatment of dystonic tremor: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 759-769.	1.9	105
254	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. Neurotherapeutics, 2014, 11, 6-23.	4.4	119
255	Initiating dopaminergic treatment in Parkinson's disease. Lancet, The, 2014, 384, 1164-1166.	13.7	17
256	Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. Movement Disorders, 2014, 29, 1707-1709.	3.9	16
257	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2014, 20, 222-225.	2.2	25
258	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 2014, 29, 454-462.	3.9	379
259	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. Parkinsonism and Related Disorders, 2014, 20, 915-918.	2.2	17
260	From psychogenic movement disorder to functional movement disorder: It's time to change the name. Movement Disorders, 2014, 29, 849-852.	3.9	125
261	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	10.2	245
262	The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathologica Communications, 2013, 1, 2.	5.2	205
263	Clinicopathological review of pallidonigro-luysian atrophy. Movement Disorders, 2013, 28, 274-281.	3.9	14
264	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Movement Disorders, 2013, 28, 1980-1986.	3.9	39
265	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement Disorders, 2013, 28, 1838-1846.	3.9	122
266	Commentary. Movement Disorders, 2013, 28, 1806-1807.	3.9	1
267	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics, 2013, 14, 11-22.	1.4	131
268	Hemiballismâ€“Hemichorea. , 2013, , 151-161.		3
269	Î±-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology, 2013, 73, 155-169.	5.3	255
270	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 151-156.	4.8	11



#	ARTICLE	IF	CITATIONS
271	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. Annals of Neurology, 2013, 73, 565-575.	5.3	67
272	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.1	1,445
273	Caffeine consumption and risk of dyskinesia in <scp>CALM</scp>â€<scp>PD</scp>. Movement Disorders, 2013, 28, 380-383.	3.9	51
274	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurology, The, 2013, 12, 514-524.	10.2	126
275	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. Annals of Neurology, 2013, 73, 537-545.	5.3	128
276	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	3.9	1,754
277	Trial designs used to study neuroprotective therapy in Parkinson's disease. Movement Disorders, 2013, 28, 86-95.	3.9	59
278	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 130-135.	1.9	103
279	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology, 2013, 80, 1698-1701.	1.1	178
280	Mutations in GNAL cause primary torsion dystonia. Nature Genetics, 2013, 45, 88-92.	21.4	281
281	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 348-350.	4.3	10
282	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. JAMA Neurology, 2013, 70, 1359.	9.0	132
283	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 67-75.	1.5	47
284	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. Movement Disorders, 2013, 28, 405-406.	3.9	0
285	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. Canadian Journal of Neurological Sciences, 2013, 40, 389-402.	0.5	27
286	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408.	3.9	0
287	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurology, The, 2012, 11, 643-650.	10.2	46
288	Psychogenic facial movement disorders: Clinical features and associated conditions. Movement Disorders, 2012, 27, 1544-1551.	3.9	93

#	ARTICLE	IF	CITATIONS
289	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	3.2	94
290	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 725-729.	1.9	46
291	Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.	1.1	252
292	Investigation of C9orf72 in 4 Neurodegenerative Disorders. <i>Archives of Neurology</i> , 2012, 69, 1583.	4.5	89
293	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	3.9	115
294	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.	0.6	32
295	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525.	4.4	123
296	Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.	3.9	140
297	Multiple system atrophy—parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2012, 27, 1186-1190.	3.9	164
298	Stereotypies: A critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012, 27, 179-185.	3.9	93
299	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , 2012, 27, 690-695.	3.9	45
300	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012, 27, 794-794.	3.9	14
301	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 283-283.	5.3	4
302	Psychogenic dystonia. , 2012, , 307-319.		0
303	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.	1.1	30
304	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.	3.9	18
305	Psychogenic movement disorders: Past developments, current status, and future directions. <i>Movement Disorders</i> , 2011, 26, 1175-1186.	3.9	42
306	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	3.9	20

#	ARTICLE	IF	CITATIONS
307	Pardopruxon in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Movement Disorders, 2011, 26, 1464-1476.	3.9	38
308	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Movement Disorders, 2011, 26, 775-783.	3.9	128
309	Crossing the borders between neurology and psychiatry in functional neurological disorders. Movement Disorders, 2011, 26, 1373-1374.	3.9	1
310	Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. Movement Disorders, 2011, 26, 2296-2297.	3.9	15
311	Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. Movement Disorders, 2011, 26, 2297-2298.	3.9	7
312	The curious case of phenocopies in families with genetic Parkinson's disease. Movement Disorders, 2011, 26, 1793-1802.	3.9	40
313	Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. Movement Disorders, 2011, 26, 2427-2431.	3.9	44
314	Impulse control disorders in parkinson disease: A multicenter case-control study. Annals of Neurology, 2011, 69, 986-996.	5.3	361
315	Movement Disorders on YouTube – Caveat Spectator. New England Journal of Medicine, 2011, 365, 1160-1161.	27.0	77
316	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. Journal of Neurosurgery, 2011, 114, 1428-1431.	1.6	20
317	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. Archives of Neurology, 2011, 68, 1550.	4.5	397
318	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. Brain, 2011, 134, 2096-2105.	7.6	83
319	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 364-368.	1.9	40
320	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. Journal of Human Genetics, 2011, 56, 671-675.	2.3	10
321	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. Experimental Brain Research, 2010, 206, 1-13.	1.5	9
322	Extrastriatal dopaminergic dysfunction in tourette syndrome. Annals of Neurology, 2010, 67, 170-181.	5.3	92
323	Dystonia in complex regional pain syndrome type I. Annals of Neurology, 2010, 67, 412-414.	5.3	24
324	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Annals of Neurology, 2010, 68, 18-27.	5.3	330

#	ARTICLE	IF	CITATIONS
325	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	5.3	132
326	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.	5.3	117
327	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.	3.9	382
328	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	3.9	130
329	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	3.9	106
330	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	3.9	25
331	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	3.9	3
332	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	3.9	32
333	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.	3.9	54
334	The grasp reflex: A symptom in need of treatment. <i>Movement Disorders</i> , 2010, 25, 2479-2485.	3.9	9
335	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS4PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	3.9	20
336	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.	3.9	22
337	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010, 16, 1223-1226.	30.7	83
338	The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.	2.9	125
339	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.5	1,244
340	Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 252-272.	0.1	1
341	LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	3.1	9
342	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1460.	4.5	326

#	ARTICLE	IF	CITATIONS
343	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.1	52
344	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-2766.	5.4	140
345	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.5	172
346	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009, 66, 110-114.	5.3	106
347	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	5.3	80
348	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.	5.3	225
349	Cerebral blood flow changes induced by pedunculo pontine nucleus stimulation in patients with advanced Parkinson's disease: A [ <sup>15</sup> O] H <sub>2</sub> O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	3.6	99
350	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	3.9	104
351	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	3.9	138
352	Hereditary parkinsonism: Parkinson disease look-alikes? An algorithm for clinicians to "PARK" genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.	3.9	62
353	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	3.9	48
354	ATP13A2 variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.	3.9	62
355	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.	3.9	11
356	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.	3.9	22
357	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.	3.6	303
358	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-66.	5.4	83
359	The spectrum of orolingual tremor? A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.	3.9	46
360	The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.	3.9	20

#	ARTICLE	IF	CITATIONS
361	A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Movement Disorders, 2008, 23, 297-299.	3.9	266
362	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. Movement Disorders, 2008, 23, 653-659.	3.9	122
363	Levodopa-related motor complications-Phenomenology. Movement Disorders, 2008, 23, S509-S514.	3.9	93
364	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. Movement Disorders, 2008, 23, 925-925.	3.9	0
365	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. Movement Disorders, 2008, 23, 1051-1054.	3.9	56
366	Electrophysiological features of myoclonus and dystonia. Movement Disorders, 2008, 23, 2055-2061.	3.9	42
367	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
368	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
369	Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurology, The, 2008, 7, 927-938.	10.2	106
370	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain, 2008, 131, 2720-2728.	7.6	460
371	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. Archives of Neurology, 2008, 65, 716.	4.5	295
372	Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. Journal of Clinical Neurophysiology, 2008, 25, 304-312.	1.7	24
373	Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.		6
374	Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?. Nature Clinical Practice Neurology, 2007, 3, 134-135.	2.5	16
375	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. Neurology, 2007, 69, 1062-1063.	1.1	7
376	Factors Associated With Dopaminergic Drug-Related Pathological Gambling in Parkinson Disease. Archives of Neurology, 2007, 64, 212.	4.5	322
377	The progression of Parkinson disease. Neurology, 2007, 68, 948-952.	1.1	109
378	Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. Journal of Neuroscience, 2007, 27, 6029-6036.	3.6	65

#	ARTICLE	IF	CITATIONS
379	Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. Archives of Neurology, 2007, 64, 886.	4.5	95
380	Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. Journal of Neurophysiology, 2007, 98, 720-729.	1.8	129
381	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	1.7	104
382	The many faces of corticobasal degeneration. Parkinsonism and Related Disorders, 2007, 13, S336-S340.	2.2	91
383	Motor and non-motor fluctuations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 157-184.	1.8	6
384	Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. Sleep, 2007, 30, 823-827.	1.1	95
385	Antidepressants and psychosis in Parkinson disease: a case series. International Journal of Geriatric Psychiatry, 2007, 22, 601-604.	2.7	21
386	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	3.9	1,097
387	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. Movement Disorders, 2007, 22, 328-333.	3.9	37
388	Gait abnormalities in psychogenic movement disorders. Movement Disorders, 2007, 22, 395-399.	3.9	125
389	Punding prevalence in Parkinson's disease. Movement Disorders, 2007, 22, 1179-1181.	3.9	125
390	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. Movement Disorders, 2007, 22, 813-821.	3.9	97
391	Refinement of the DYT15 locus in myoclonus dystonia. Movement Disorders, 2007, 22, 888-892.	3.9	41
392	Orthostatic tremor in progressive supranuclear palsy. Movement Disorders, 2007, 22, 1192-1194.	3.9	17
393	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Movement Disorders, 2007, 22, 990-997.	3.9	106
394	Sustained relief of dystonia following cessation of deep brain stimulation. Movement Disorders, 2007, 22, 1958-1962.	3.9	59
395	Benign hereditary chorea revisited: A journey to understanding. Movement Disorders, 2007, 22, 2297-2305.	3.9	50
396	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. Movement Disorders, 2007, 22, 2113-2116.	3.9	33



#	ARTICLE	IF	CITATIONS
397	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. Movement Disorders, 2007, 22, 2292-2293.	3.9	11
398	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	3.9	221
399	GDNF in Parkinson's disease: The perils of post-hoc power. Journal of Neuroscience Methods, 2007, 163, 193-196.	2.5	13
400	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurology, The, 2007, 6, 652-662.	10.2	290
401	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology, 2006, 66, 845-851.	1.1	371
402	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Review of Neurotherapeutics, 2006, 6, 1695-1705.	2.8	71
403	GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology, The, 2006, 5, 200-202.	10.2	35
404	Neuroprotection in Parkinson's disease: and now for something completely different?. Lancet Neurology, The, 2006, 5, 990-991.	10.2	20
405	Homozygous and heterozygous <i>PINK1</i> mutations: Considerations for diagnosis and care of Parkinson's disease patients. Movement Disorders, 2006, 21, 875-879.	3.9	31
406	Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders, 2006, 21, 136-141.	3.9	163
407	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. Movement Disorders, 2006, 21, 1578-1594.	3.9	99
408	Deep brain stimulation for Parkinson's disease. Movement Disorders, 2006, 21, S168-S170.	3.9	62
409	Deep brain stimulation: Preoperative issues. Movement Disorders, 2006, 21, S171-S196.	3.9	260
410	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. Movement Disorders, 2006, 21, S290-S304.	3.9	811
411	Development of dyskinesias in a 5-year trial of ropinirole and levodopa. Movement Disorders, 2006, 21, 1844-1850.	3.9	145
412	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Movement Disorders, 2006, 21, 1941-1946.	3.9	245
413	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. Movement Disorders, 2006, 21, 2251-2254.	3.9	11
414	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	5.3	890



#	ARTICLE	IF	CITATIONS
415	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	5.3	240
416	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	5.3	195
417	Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2006, 96, 3248-3256.	1.8	520
418	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	7.6	286
419	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.	0.2	0
420	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.	3.6	46
421	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.5	4
422	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.	3.9	107
423	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.	3.9	27
424	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.	3.9	63
425	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , 2005, 166, 230-236.	1.5	72
426	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.	1.4	36
427	Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.		1
428	Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.		2
429	Corticobasal degeneration. , 2005, , 682-696.		0
430	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.		0
431	Approach to the patient presenting with parkinsonism. , 2005, , 551-560.		0
432	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0

#	ARTICLE	IF	CITATIONS
433	Multiple system atrophy. , 2005, , 623-662.		2
434	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. Journal of Neurosurgery, 2005, 103, 246-251.	1.6	50
435	Apraxia in movement disorders. Brain, 2005, 128, 1480-1497.	7.6	228
436	Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. Journal of Clinical Psychiatry, 2005, 66, 1529-1534.	2.2	125
437	Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. Archives of Neurology, 2004, 61, 1898-904.	4.5	162
438	Clinical Findings in a Large Family With a Parkin Ex31"40 Mutation. Archives of Neurology, 2004, 61, 701.	4.5	24
439	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. Brain, 2004, 127, 1252-1268.	7.6	134
440	Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. Journal of Neurophysiology, 2004, 92, 1937-1943.	1.8	55
441	Involvement of human thalamus in the preparation of self-paced movement. Brain, 2004, 127, 2717-2731.	7.6	111
442	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology, The, 2004, 3, 309-316.	10.2	302
443	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Annals of Neurology, 2004, 55, 761-765.	5.3	95
444	Bilateral globus pallidus stimulation for Huntington's disease. Annals of Neurology, 2004, 56, 290-294.	5.3	207
445	Chorein detection for the diagnosis of chorea"acanthocytosis. Annals of Neurology, 2004, 56, 299-302.	5.3	186
446	Gestes antagonistes in psychogenic dystonia. Movement Disorders, 2004, 19, 331-332.	3.9	36
447	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. Movement Disorders, 2004, 19, 580-583.	3.9	9
448	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. Movement Disorders, 2004, 19, 534-543.	3.9	4
449	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. Movement Disorders, 2004, 19, 969-972.	3.9	84
450	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. Movement Disorders, 2004, 19, 1209-1214.	3.9	46

#	ARTICLE	IF	CITATIONS
451	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.	3.9	240
452	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	3.9	219
453	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004, 19, 1485-1492.	3.9	10
454	Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 2004, 9, 188-192.	3.9	37
455	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.	1.8	30
456	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.	2.1	31
457	Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.	1.1	278
458	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.	1.2	8
459	Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.	0.7	30
460	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.5	174
461	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.	10.2	217
462	Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.	3.9	29
463	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	3.9	17
464	Corticobasal degeneration: Selected developments. <i>Movement Disorders</i> , 2003, 18, 51-56.	3.9	40
465	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.	3.9	191
466	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003, 18, 1482-1491.	3.9	81
467	Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.	5.3	246
468	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S15-S19.	5.3	496

#	ARTICLE	IF	CITATIONS
469	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	5.3	820
470	Benign hereditary chorea: Clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003, 54, 244-247.	5.3	90
471	Psychogenic Movement Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, S94-S100.	0.5	97
472	Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.	1.4	32
473	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495.	1.6	306
474	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.	7.6	258
475	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. <i>Neurosurgery</i> , 2003, 53, 1095-1105.	1.1	76
476	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003, 61, 1601-1604.	1.1	204
477	The Fragile X Premutation Presenting as Essential Tremor. <i>Archives of Neurology</i> , 2003, 60, 117.	4.5	162
478	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , 2003, 60, 1985-1987.	1.1	97
479	Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. <i>Archives of Neurology</i> , 2003, 60, 1554.	4.5	44
480	Predicting Motor Decline and Disability in Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1724.	4.5	179
481	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002, 97, 1152-1166.	1.6	267
482	Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 455.	7.4	509
483	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	1.1	314
484	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002, 125, 1196-1209.	7.6	645
485	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.	0.7	122
486	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	1.1	227

#	ARTICLE	IF	CITATIONS
487	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	3.9	183
488	Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. <i>Movement Disorders</i> , 2002, 17, S94-S101.	3.9	150
489	Sleepiness and Sleep Attacks in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 385-390.	0.2	0
490	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002, 89, 77-83.	0.8	7
491	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001, 112, 600-607.	1.5	88
492	Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. <i>Brain</i> , 2001, 124, 2105-2118.	7.6	168
493	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	1.1	51
494	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	1.1	35
495	Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.	3.9	4
496	69-Year-old man with gait disturbance and parkinsonism. <i>Movement Disorders</i> , 2001, 16, 548-561.	3.9	1
497	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000, 123, 746-758.	7.6	103
498	Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.	27.0	263
499	Surgery for Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 1118.	4.5	83
500	Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.	1.8	255
501	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	27.0	1,467
502	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999, 122, 405-416.	7.6	153
503	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.	0.5	99
504	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999, 90, 468-477.	1.6	38

#	ARTICLE	IF	CITATIONS
505	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. Movement Disorders, 1999, 14, 674-680.	3.9	57
506	Letters to the Editor. Movement Disorders, 1998, 13, 851-854.	3.9	53
507	New developments in understanding the etiology of Parkinson's disease and in its treatment. Current Opinion in Neurobiology, 1998, 8, 783-790.	4.2	82
508	Parkinson's Disease. New England Journal of Medicine, 1998, 339, 1044-1053.	27.0	1,876
509	Parkinson's Disease. New England Journal of Medicine, 1998, 339, 1130-1143.	27.0	1,147
510	Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. Canadian Journal of Neurological Sciences, 1998, 25, 300-305.	0.5	74
511	Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. Stereotactic and Functional Neurosurgery, 1998, 71, 153-163.	1.5	27
512	Pallidotomy for Parkinson's Disease. Neurosurgery Clinics of North America, 1998, 9, 325-336.	1.7	47
513	Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. Brain Pathology, 1998, 8, 355-365.	4.1	89
514	Pallidotomy for Tremor. Movement Disorders, 1998, 13, 107-110.	3.9	23
515	Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. New England Journal of Medicine, 1997, 337, 1036-1043.	27.0	453
516	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nature Medicine, 1997, 3, 671-674.	30.7	216
517	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. Annals of Neurology, 1997, 41, 834-835.	5.3	53
518	Teaching tape for the motor section of the toronto western spasmodic torticollis scale. Movement Disorders, 1997, 12, 570-575.	3.9	177
519	Globus pallidus internus pallidotomy for generalized dystonia. Movement Disorders, 1997, 12, 865-870.	3.9	379
520	Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. Canadian Journal of Neurological Sciences, 1996, 23, 198-203.	0.5	49
521	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. Movement Disorders, 1996, 11, 448-449.	3.9	16
522	Psychogenic Dystonia: a Review of 18 Cases. Canadian Journal of Neurological Sciences, 1995, 22, 136-143.	0.5	137

#	ARTICLE	IF	CITATIONS
523	“Weight-holding tremor”: An unusual task-specific form of essential tremor?. Movement Disorders, 1995, 10, 228-229.	3.9	7
524	Letters to the editor. Movement Disorders, 1995, 10, 235-237.	3.9	7
525	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. Movement Disorders, 1995, 10, 489-495.	3.9	30
526	Letters to the editor. Movement Disorders, 1995, 10, 527-529.	3.9	31
527	Chronic acquired hepatocerebral degeneration: Case reports and new insights. Movement Disorders, 1995, 10, 714-722.	3.9	83
528	Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. Movement Disorders, 1994, 9, 358-366.	3.9	18
529	Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. Movement Disorders, 1994, 9, 508-520.	3.9	188
530	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. Canadian Journal of Neurological Sciences, 1994, 21, 311-318.	0.5	61
531	Parietal Pick's disease mimicking cortical “basal ganglionic degeneration. Neurology, 1994, 44, 1436-1436.	1.1	95
532	Hemiballism in multiple sclerosis. Movement Disorders, 1988, 3, 88-94.	3.9	66
533	Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.		7
534	High Dose Anticholinergic Therapy in Adult Dystonia. Canadian Journal of Neurological Sciences, 1986, 13, 42-46.	0.5	35
535	Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. Canadian Journal of Neurological Sciences, 1985, 12, 125-128.	0.5	49
536	Treatment of Parkinson's disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. Canadian Journal of Neurological Sciences, 1984, 11, 210-220.	0.5	40
537	Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. Clinical Neuropharmacology, 1982, 5, 375-388.	0.7	30
538	Anticholinergics in Adult-Onset Focal Dystonia. Canadian Journal of Neurological Sciences, 1982, 9, 313-319.	0.5	50
539	Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.		0
540	The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.		0

#	ARTICLE	IF	CITATIONS
541	Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia. Movement Disorders Clinical Practice, 0, , .	1.5	1
542	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	1.2	3